Access & Support

ForgingBridges® is committed to
providing continuous support

Program Overview
Access Resources

Actor portrayals.

Access Resources icon

Find a variety of resources to help you, your patients,
and office staff along
the way

Office Staff Resources

Start Form

Start Form

Use this form to prescribe
Attruby for your appropriate
patients and enroll them in
the ForgingBridges®
Support Program.

Download
Free Trial Program Form

Free Trial Program Form

Use this form to prescribe a
1-month supply of Attruby at no cost. New Attruby patients only.

Download
Access & Affordability Guide

Access & Affordability Guide

Provides information on
accessing Attruby and outlines affordability options available
to eligible patients.

Download
video thumbnail play 05:02

HCP ForgingBridges Support Video

Find out what support and resources may be available to your patients and office staff.

Watch Now

Patient and Caregiver Resources

Medicare Part D Patient Guide

Medicare Part D Patient Guide

Educates patients with Medicare
Part D on the Medicare Prescription Payment Plan and eligibility for
low-income subsidy.

Download
Patient Consent Form

Patient Consent Form

Your patient may sign this standalone Patient Consent Form OR the patient section within the Attruby Start Form above to enroll in ForgingBridges.

Download
Commercial Copay Assistance Program Brochure

Commercial Copay Assistance Program Brochure

Provides your patients with information about the ForgingBridges Copay
Assistance Program.

Download
Program Overview
Access Resources
Access Resources icon

HCP ForgingBridges Support Video

hospital

See the helpful resources available to you, your staff,
and your patients

See Resources

Indication and Important safety information

INDICATION

Attruby® (acoramidis) is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION

Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation.

Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

Laboratory Tests
Mean increase in serum creatinine of 0.2 and 0.0 mg/dL and a mean decrease in eGFR of 8.2 and 0.7 mL/min/1.73 m2 was observed in the adults with ATTR-CM treated with Attruby versus placebo, respectively, at Day 28 and then stabilized. These changes were reversible after treatment discontinuation.

Use in Specific Populations

Pregnancy & Lactation: There are no data on the use of Attruby in pregnant women. Animal data have not shown developmental risk associated with the use of Attruby in pregnancy. There are no available data on the presence of Attruby in either human or animal milk or the effects of the drug on the breastfed infant or maternal milk production.

Please see Full Prescribing Information including Patient Information.

INDICATION AND IMPORTANT
SAFETY INFORMATION

INDICATION

Attruby® (acoramidis) is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION

Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation.

Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

Laboratory Tests
Mean increase in serum creatinine of 0.2 and 0.0 mg/dL and a mean decrease in eGFR of 8.2 and 0.7 mL/min/1.73 m2 was observed in the adults with ATTR-CM treated with Attruby versus placebo, respectively, at Day 28 and then stabilized. These changes were reversible after treatment discontinuation.

Use in Specific Populations

Pregnancy & Lactation: There are no data on the use of Attruby in pregnant women. Animal data have not shown developmental risk associated with the use of Attruby in pregnancy. There are no available data on the presence of Attruby in either human or animal milk or the effects of the drug on the breastfed infant or maternal milk production.

Please see Full Prescribing Information including Patient Information.